Circulatory dipeptidyl peptidase 3 (cDPP3) is a potential biomarker for early detection of secondary brain injury after aneurysmal subarachnoid hemorrhage.
Aneurysmal SAH
Circulatory DPP3
Delayed cerebral ischemia (DCI)
Infarction
Ruptured cerebral aneurysm
Journal
Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403
Informations de publication
Date de publication:
15 Mar 2021
15 Mar 2021
Historique:
received:
25
12
2020
revised:
24
01
2021
accepted:
28
01
2021
pubmed:
8
2
2021
medline:
15
5
2021
entrez:
7
2
2021
Statut:
ppublish
Résumé
Delayed cerebral ischemia (DCI) is a common complication after aneurysmal subarachnoid hemorrhage (aSAH) that can culminate in secondary brain damage. Although it remains one of the main preventable causes of aSAH-related morbidity, there is still a lack of prognostic criteria for identification of patients at risk of developing DCI. Because elevated circulatory levels of the enzyme dipeptidyl peptidase 3 (cDPP3) were recently identified as a potential biomarker for outcome prediction in critically ill patients, we evaluated the time-course of changes in cDPP3 levels after aSAH. cDPP3 levels were quantified in serum obtained from 96 confirmed aSAH patients during the early (EP: d Significantly higher cDPP3 levels during CP (d Our results provide first evidence that cDPP3 could serve as a promising biomarker for early diagnosis of DCI-related infarctions in poor grade aSAH patients.
Identifiants
pubmed: 33549902
pii: S0022-510X(21)00026-5
doi: 10.1016/j.jns.2021.117333
pii:
doi:
Substances chimiques
Biomarkers
0
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
EC 3.4.14.-
DPP3 protein, human
EC 3.4.14.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117333Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.